#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
If you are a parent or caregiver of a teenager, this research reinforces why cannabis medicine should only be considered for adolescents under direct physician supervision with clear medical necessity, and why recreational teen use carries real psychiatric risk.
Adolescent cannabis use has consistently been associated with increased risk of psychiatric disorders in the clinical literature, and new large-scale data continues to reinforce this concern. The developing brain is particularly vulnerable to exogenous cannabinoids, and early exposure during critical neurodevelopmental windows may alter endocannabinoid signaling in ways that predispose teens to conditions like psychosis, anxiety disorders, and depression. This is precisely why responsible cannabis medicine physicians advocate strongly against adolescent recreational use while still recognizing the therapeutic potential of cannabinoids in carefully supervised pediatric cases.
“I have treated thousands of patients with cannabis medicine and I can tell you plainly that the teenage brain is not the place for unsupervised THC exposure, and studies like this are exactly why age, dose, and clinical oversight matter so much in this field.”
🧠 A new large-scale study adds to the growing body of evidence that adolescent cannabis use is associated with elevated psychiatric risk, including psychosis, depression, and anxiety disorders. From a clinical standpoint, this aligns with what we understand about the endocannabinoid system’s role in neurodevelopment, as exogenous THC during critical brain maturation periods can dysregulate signaling pathways that govern mood, cognition, and stress response. ️ It is important to distinguish between unsupervised teen recreational use and carefully monitored medical cannabis therapy, because the two carry vastly different risk profiles. ️ At CED Clinic, when we do treat younger patients, it involves precise dosing, parental involvement, and ongoing psychiatric monitoring. Studies like this do not discredit cannabis medicine; they reinforce that age, intention, and clinical oversight are everything.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Dr Caplan wrote a deeper review of the JAMA Health Forum paper for readers who want a more critical eye on methods, limitations, and what the data can (and cannot) prove: Adolescent Cannabis Use and Psychosis Risk – Study Review
Have thoughts on this? Share it:
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
